IgA nephropathy
Conditions
Interventions
experiment group 1:The first 12 weeks after taking azilsartan to valsartan
experiment group 2:After taking valsartan in the first 12 weeks, it was changed to azilsartan.
Sponsors
Chinese Cardiovascular Association-HX Fund
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1 ) Voluntary signing of informed consent. 2 ) Age 18-75 years old. 3 ) Non-dialysis patients diagnosed with IgA nephropathy by renal biopsy. 4 ) 24-hour urine volume > 1000ml 5 ) 24-hour urinary protein > 0.5g or urinary ACR>300mg/g.
Exclusion criteria
Exclusion criteria: 1 ) Fertility non-contraceptive, pregnant or lactating women. 2 ) severe hypertension ( msDBP = 110 mmHg and / or msSBP = 180 mmHg ). 3 ) Neurovascular edema, drug-related or other causes reported by patients. 4 ) Patients currently diagnosed with heart failure ( NYHA class III-IV ). 5 ) LVEF 6.0mmol / L during the visit ; aLT or AST > 2 times the upper limit of normal ( ULN ) or TBL > 2 xULN or ALP > 1.5 xULN. 13 ) The researchers believe that there are no provisions in the program that may pose a high risk to patients, or prevent patients from complying with the requirements of the study and any medical or surgical conditions that cannot complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ACR; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;24-hour urinary protein;LVEDD;Left ventricular posterior wall thickness; | — |
Countries
China
Contacts
Public ContactChen Junzhe
The Third Affiliated Hospital of Southern Medical University
Outcome results
None listed